$730.57
-4.63-0.63%
마지막 업데이트: Oct 5, 10:07 AM
$735.30
0.10.01%
Benzinga
Benzinga
Benzinga
월요일, 10월 05
Benzinga
© 2026 Benzinga | All Rights Reserved
Regeneron Pharmaceuticals (REGN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $10.34 | $8.38 | $9.69 | $8.84 |
| Actual | $14.29 | $9.47 | $11.44 | $11.83 |
| Surprise | +38.2% | +13.0% | +18.1% | +33.8% |
| Revenue | ||||
| Estimate | $3.81B | $3.47B | $3.80B | $3.59B |
| Actual | $4.29B | $3.60B | $3.88B | $3.75B |
| Surprise | +12.5% | +3.75% | +2.27% | +4.47% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $15.33 | $14.96 | $9.49 | $11.06 |
| Revenue | ||||
| Consensus | $4.52B | $4.60B | — | — |
| 회계 분기 | 보고된 날짜 | 실제 EPS | 예상 EPS | 놀라다 % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $14.29 | $10.34 | 38.2 % |
| Q1 | Apr 29, 2026 | $9.47 | $8.38 | 13.0 % |
| Q4 | Jan 30, 2026 | $11.44 | $9.69 | 18.1 % |
| Q3 | Oct 28, 2025 | $11.83 | $8.84 | 33.8 % |
| 회계 분기 | 보고된 날짜 | 실제 수익 | 예상 수익 | 놀라다 % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $4.29B | $3.81B | 12.5 % |
| Q1 | Apr 29, 2026 | $3.61B | $3.47B | 3.75 % |
| Q4 | Jan 30, 2026 | $3.88B | $3.80B | 2.27 % |
| Q3 | Oct 28, 2025 | $3.75B | $3.59B | 4.47 % |